Neurogene (NGNE) Cash from Investing Activities (2013 - 2026)

Neurogene (NGNE) has 14 years of Cash from Investing Activities data on file, last reported at $46.2 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 202.65% year-over-year to $46.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $105.3 million (up 152.58% YoY) and the FY2025 annual result came in at $14.0 million, up 111.18% from the prior year.
• Cash from Investing Activities climbed to $46.2 million in Q1 2026, from $29.6 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $65.4 million in Q4 2022 to a low of -$102.6 million in Q4 2024.
• A 5-year average of -$2.4 million and a median of -$82000.0 in 2023 frame the typical range for Cash from Investing Activities.
• The widest YoY moves for Cash from Investing Activities: up 103324.14% in 2024, down 35224.39% in 2024.
• Tracing NGNE's Cash from Investing Activities over 5 years: stood at $65.4 million in 2022, then plunged by 60.49% to $25.8 million in 2023, then sank by 497.27% to -$102.6 million in 2024, then surged by 128.85% to $29.6 million in 2025, then soared by 56.17% to $46.2 million in 2026.
• The last three Cash from Investing Activities figures came in at $46.2 million (Q1 2026), $29.6 million (Q4 2025), and $22.0 million (Q3 2025), per Business Quant data.